Status:
RECRUITING
CYP1A2 and ADORA2A Genotypes and Endurance Performance.
Lead Sponsor:
Masaryk University
Conditions:
Healthy
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
The aim of this randomized, double-blind, placebo-controlled experiment will be to assess the potential effect of the selected gene polymorphism (CYP1A2, ADORA2A) on performance after caffeine ingesti...
Detailed Description
This randomized, double-blinded, placebo-controlled, within-subjects counter-measured study design will include 60 males and females that fall between the given age range (18-35 years). Participants ...
Eligibility Criteria
Inclusion
- healthy person
- any training status
- within age limits
- without contraindications to perform the test on a bicycle trainer
- No contraindications to caffeine intake
Exclusion
- Pregnancy
- Breast feeding
- Cardiovascular disease
- Hypertension
- Liver disease in the previous two months
- Taking drugs that can affect liver function
- Illness in the period of 14 days before the start of the research
- Use of caffeine during research
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06547307
Start Date
August 1 2024
End Date
March 1 2025
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Masaryk University
Brno, Czechia